Alphamab Oncology (HKSE:09966) Change In Receivables : HK$6.1 Mil (TTM As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Change In Receivables?

Alphamab Oncology's change in receivables for the quarter that ended in Jun. 2024 was HK$-7.4 Mil. It means Alphamab Oncology's Accounts Receivable increased by HK$7.4 Mil from Dec. 2023 to Jun. 2024 .

Alphamab Oncology's change in receivables for the fiscal year that ended in Dec. 2023 was HK$26.3 Mil. It means Alphamab Oncology's Accounts Receivable declined by HK$26.3 Mil from Dec. 2022 to Dec. 2023 .

Alphamab Oncology's Accounts Receivable for the quarter that ended in Jun. 2024 was HK$14.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Alphamab Oncology's Days Sales Outstanding for the six months ended in Jun. 2024 was 13.84.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Alphamab Oncology's liquidation value for the six months ended in Jun. 2024 was HK$1,061.2 Mil.

Alphamab Oncology Change In Receivables Historical Data

The historical data trend for Alphamab Oncology's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Change In Receivables Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-36.92

-23.42

-27.11

28.79

26.30

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Receivables	Get a 7-Day Free Trial									28.35	1.79	12.79	13.51	-7.43

Alphamab Oncology Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$6.1 Mil.

Alphamab Oncology (HKSE:09966) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Alphamab Oncology's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	14.174	/	186.846	*	91
=	13.84

2. In Ben Graham's calculation of liquidation value, Alphamab Oncology's accounts receivable are only considered to be worth 75% of book value:

Alphamab Oncology's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1568.078	-	552.537	+	0.75 * 14.174	+	0.5 * 70.151
=	1,061.2

Alphamab Oncology Change In Receivables Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Executives

South Dakota Trust Company Llc	2301 Trustee
Xu Ting	2305 Beneficiary of a trust
Liu Yang	2307 Founder of a discretionary trust who can infl
Rubymab Ltd.	2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology Headlines

No Headlines